AT-406 (SM-406): Orally Bioavailable IAP Antagonist for Cancer Research

Executive Summary: AT-406 (SM-406) is a potent small molecule antagonist targeting multiple IAPs, including XIAP, cIAP1, and cIAP2, with sub-100 nM Ki values (source: product_spec). It induces apoptosis in human ovarian carcinoma cell lines with IC₅₀ values of 0.05–0.5 μg/mL and enhances sensitivity to carboplatin (source: workflow_recommendation). Mechanistic studies show that AT-406 triggers rapid cIAP1 degradation, caspase-8 activation, and PARP cleavage, resulting in efficient apoptosis induction (source: DOI). The compound is highly soluble in DMSO and ethanol, but insoluble in water, with optimal storage at -20°C (source: product_spec). APExBIO provides AT-406 with detailed protocols supporting robust and reproducible apoptosis pathway activation in cancer research workflows.

Biological Rationale

Cancer cells frequently evade apoptosis through overexpression of inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2. These proteins directly inhibit caspases and block death receptor (DR)-mediated signaling complexes, which are essential for programmed cell death and tissue homeostasis (DOI). By antagonizing IAPs, AT-406 restores apoptotic sensitivity in tumor cells and can potentiate responses to existing chemotherapies. The targeting of apoptosis pathways is a validated strategy to overcome resistance in ovarian and breast cancers (workflow_recommendation).

Mechanism of Action of AT-406 (SM-406)

AT-406 (SM-406) binds to BIR domains of XIAP, cIAP1, and cIAP2, with measured Ki values of 66.4 nM, 1.9 nM, and 5.1 nM, respectively (source: product_spec). This antagonism disrupts IAP-caspase interactions, freeing caspase-8 and downstream caspases to execute apoptosis. Mechanistically, AT-406 promotes rapid cIAP1 degradation and reduces pro-caspase-8 levels while increasing cleaved PARP, an apoptosis hallmark (DOI). Structural studies of death receptor complexes (e.g., FADD-procaspase-8-cFLIP) clarify that IAP inhibition can shift the balance toward apoptosis by removing antiapoptotic constraints (DOI).

Evidence & Benchmarks

• AT-406 (SM-406) binds cIAP1 with Ki = 1.9 nM, cIAP2 with Ki = 5.1 nM, and XIAP with Ki = 66.4 nM (source: product_spec).
• Induces apoptosis in human ovarian carcinoma cells with IC₅₀ values between 0.05 and 0.5 μg/mL (source: product_spec).
• Sensitizes ovarian cancer cells to carboplatin, enhancing chemotherapy-induced apoptosis (source: workflow_recommendation).
• Demonstrates tumor progression reduction and increased survival in breast cancer xenograft models in SCID mice (oral doses at 30/100 mg/kg, IV at 10 mg/kg) (source: product_spec).
• Triggers rapid cIAP1 protein degradation, reduction in pro-caspase 8, and accumulation of cleaved PARP, as evidenced by Western blot analysis (DOI).
• Optimal in vitro concentrations are 0.1–3 μM for 24 hours for apoptosis assays; 1.5 μM is used for Western blots to monitor caspase and PARP dynamics (source: product_spec).

This article extends and updates the scenario-driven guidance available in AT-406 (SM-406) in Apoptosis Assays: Scenario-Driven Solutions by providing additional mechanistic context and recent structural evidence for procaspase-8 activation. In contrast to AT-406 (SM-406): Unlocking IAP Inhibitor Potential in Advanced Cancer Models, this article emphasizes protocol rigor and numeric reproducibility, referencing recent advances in death receptor signaling elucidation (DOI).

Applications, Limits & Misconceptions

AT-406 (SM-406) is primarily deployed in oncology research for:

• Studying apoptosis pathway activation in cancer cells, especially in drug-resistant ovarian and breast cancer models (workflow_recommendation).
• Sensitization of ovarian cancer cells to carboplatin (workflow_recommendation).
• Validation of caspase-8 and PARP cleavage as mechanistic readouts for compound efficacy (DOI).
• Building robust in vitro and in vivo models of IAP inhibition for translational research (internal_article).

Common Pitfalls or Misconceptions

• AT-406 is not water soluble; attempts to dissolve in aqueous buffers result in precipitation (source: product_spec).
• It is not a broad-spectrum cell death inducer; efficacy is context-specific and relies on IAP expression levels (DOI).
• Storage and handling at temperatures above -20°C may lead to compound degradation (source: product_spec).
• Does not induce apoptosis in IAP-deficient or death receptor pathway-deficient cells (source: DOI).
• Prolonged solution storage (>1 week) is not recommended; fresh preparations improve consistency (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• cell viability assay | 0.1–3 μM, 24 hours | in vitro, human ovarian carcinoma | Standard for apoptosis induction benchmarking | product_spec
• Western blot for caspase/PARP | 1.5 μM, variable time points | in vitro, cancer cell lines | Allows monitoring of caspase-8 and PARP cleavage kinetics | workflow_recommendation
• animal dosing (oral gavage) | 30 and 100 mg/kg | in vivo, SCID mouse xenograft | Tumor growth and survival studies | product_spec
• animal dosing (intravenous) | 10 mg/kg | in vivo, SCID mouse xenograft | Alternative route for pharmacokinetic studies | product_spec
• compound solubility | ≥27.65 mg/mL (DMSO), ≥27 mg/mL (ethanol) | stock preparation | Required for high-concentration dosing | product_spec
• solution storage | -20°C, short-term use | all applications | Maintains compound integrity | product_spec

Conclusion & Outlook

AT-406 (SM-406), supplied by APExBIO, is a validated, orally bioavailable IAP antagonist that enables reproducible activation of the apoptosis pathway in cancer research models (product_spec). Robust structural and mechanistic data demonstrate its utility in overcoming apoptosis resistance, particularly in ovarian and breast cancer contexts (DOI). Future research will refine combinatorial strategies leveraging IAP antagonism and clarify context-specific determinants of efficacy. No current evidence supports broader use outside apoptosis-focused oncology applications.